Endo To Pay Texas $13M Over Off-Label Lidoderm Sales
Endo Pharmaceuticals Inc. has agreed to pay Texas $13.25 million to settle whistleblower claims that it defrauded the state's Medicaid program by advertising its pain medication Lidoderm for unapproved uses, according...To view the full article, register now.
Already a subscriber? Click here to view full article